Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. adults

PLoS One. 2021 May 24;16(5):e0251963. doi: 10.1371/journal.pone.0251963. eCollection 2021.

Abstract

Background: The success of vaccination efforts to curb the COVID-19 pandemic will require broad public uptake of immunization and highlights the importance of understanding factors associated with willingness to receive a vaccine.

Methods: U.S. adults aged 65 and older enrolled in the HeartlineTM clinical study were invited to complete a COVID-19 vaccine assessment through the HeartlineTM mobile application between November 6-20, 2020. Factors associated with willingness to receive a COVID-19 vaccine were evaluated using an ordered logistic regression as well as a Random Forest classification algorithm.

Results: Among 9,106 study participants, 81.3% (n = 7402) responded and had available demographic data. The majority (91.3%) reported a willingness to be vaccinated. Factors most strongly associated with vaccine willingness were beliefs about the safety and efficacy of COVID-19 vaccines and vaccines in general. Women and Black or African American respondents reported lower willingness to vaccinate. Among those less willing to get vaccinated, 66.2% said that they would talk with their health provider before making a decision. During the study, positive results from the first COVID-19 vaccine outcome study were released; vaccine willingness increased after this report.

Conclusions: Even among older adults at high-risk for COVID-19 complications who are participating in a longitudinal clinical study, 1 in 11 reported lack of willingness to receive COVID-19 vaccine in November 2020. Variability in vaccine willingness by gender, race, education, and income suggests the potential for uneven vaccine uptake. Education by health providers directed toward assuaging concerns about vaccine safety and efficacy can help improve vaccine acceptance among those less willing.

Trial registration: Clinicaltrials.gov NCT04276441.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • COVID-19 / prevention & control*
  • COVID-19 / psychology
  • Female
  • Health Knowledge, Attitudes, Practice
  • Humans
  • Male
  • Mass Vaccination / psychology*
  • Mass Vaccination / statistics & numerical data
  • Patient Participation / psychology*
  • Patient Participation / statistics & numerical data
  • Socioeconomic Factors
  • United States
  • Vaccination Refusal / psychology*
  • Vaccination Refusal / statistics & numerical data

Associated data

  • ClinicalTrials.gov/NCT04276441

Grants and funding

The Heartline Study is supported by Johnson & Johnson (www.jnj.com) and Apple (www.apple.com). Johnson & Johnson was responsible for study design, data collection and analysis, decision to publish and preparation of the manuscript. Apple neither supported nor participated in survey development or interpretation for this article. JS, MT, LS, MG, AMN receive personal fees and/or grants from Janssen.